Article

FDA Approves New Indication of Botox Drug for Moderate-to-Severe Forehead Lines

Author(s):

OnabotulinumtoxinA is a prescription medication that works by injection into the muscles to treat frontalis muscle activity.

FDA officials have approved onabotulinumtoxinA (BOTOX Cosmetic, Allergan) for its third indication for the temporary improvement in the appearance of moderate-to-severe forehead lines associated with frontalis muscle activity in adults. OnabotulinumtoxinA is a prescription medication that works by injection into the muscles.

With this approval, onabotulinumtoxinA is the first and only neurotoxin indicated for 3 facial treatment areas in the United States. The FDA initially approved OnabotulinumtoxinA in 2002 for the temporary improvement of the appearance of moderate-to-severe frown lines between the eyebrows (glabellar lines) and received its second indication for severe crow’s feet lines in 2013.

The approval is based on data from 2 clinical trials that supported this indication for onabotulinumtoxinA. In the first study, 61% of participants met the primary endpoint, which was the reduction of the severity of forehead lines, compared with a placebo at day 30. Forty-six percent of study participants in the second trial met the primary endpoint. The researchers found similar response rates seen across 3 treatment cycles of onabotulinumtoxinA.

The most common adverse effects of onabotulinumtoxinA include discomfort or pain at the injection site, headache and eye problems, double vision, blurred vision, drooping eyelids and eyebrows, and swelling of the eyelids.

OnabotulinumtoxinA dosing units are not the same as, or comparable to, any other botulinum toxin product.

Reference

FDA approves BOTOX Cosmetic (onabotulinumtoxinA) for the temporary improvement in the appearance of moderate to severe forehead lines associated with frontalis muscle activity in adults [news release]. Dublin, Ireland. Allergan plc; October 3, 2017. allergan.com/News/News/Thomson-Reuters/FDA-Approves-BOTOX-Cosmetic-OnabotulinumtoxinA-for. Accessed October 3, 2017.

Related Videos
3 KOLs are featured in this series.
3 KOLs are featured in this series.
Image Credit: © Birdland - stock.adobe.com
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
3 KOLs are featured in this series.
3 KOLs are featured in this series.